S-Tenatoprazole
Alternative Names: Benatoprazole; S-Tenatoprazole-Na; sTU-199; STU-Na; TU-199Latest Information Update: 17 Aug 2023
Price :
$50 *
At a glance
- Originator Mitsubishi Pharma Corporation
- Developer Abbott Japan; Mitsubishi Pharma Corporation; Negma SAS; Steba Laboratories
- Class Antiulcers; Gastric antisecretories; Imidazoles; Pyridines; Small molecules
- Mechanism of Action Proton pump inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Gastro-oesophageal reflux
- Discontinued Peptic ulcer; Zollinger-Ellison syndrome
Most Recent Events
- 30 Apr 2018 Discontinued - Phase-I for Gastro-oesophageal reflux in Europe (PO) (Mitsubishi Tanabe Pharma pipeline, May 2018)
- 31 Jul 2017 Phase-I clinical trials in Gastro-oesophageal reflux in Europe (PO) (Mitsubishi Tanabe Pharma Corporation pipeline, July 2017)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Gastro-oesophageal-reflux in European Union (PO)